Citations

Clear

299 citation(s) found for "Solomon, B".

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
Li, Dalin , Debbas, Philip , McGovern, Dermot , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Hampton, Melissa, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Chiorean, Michael , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Lum, Donald , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Damas, Oriana M. , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Cheng, Susan , Group, CORALE-IBD Study, Botwin, Gregory J., Mengesha, Emebet , White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C. , McGovern, Dermot P.B.

Mayo Clinic

Inflammatory Bowel Diseases | August 23, 2022 | Volume: 29 | Issue: 6 | Pages: 883-887

10.1093/ibd/izac174 | PMID 35998072 Get It

AbstractBackgroundThe safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.MethodsWe compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.ResultsThe study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse.ConclusionThe frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
Risk of Dementia Associated With Atrial Cardiopathy: The ARIC Study
Johansen, Michelle C. , Wang, Wendy , Zhang, Michael J. , Knopman, David S. , Ndumele, Chiadi E. , Mosley, Thomas H. , Selvin, Elizabeth , Shah, Amil M. , Solomon, Scott D. , Selvin, Elizabeth , Mosley, Thomas H. , Knopman, David S. , Zhang, Michael , Ndumele, Chiadi , Gottesman, Rebecca F , Chen, Lin Y , Selvin, Elizabeth , Johansen, Michelle C , Shah, Amil , Solomon, Scott David , Gottesman, Rebecca F. , Chen, Lin Y.

Mayo Clinic

Journal of the American Heart Association | August 10, 2022 | Volume: 11 | Issue: 16 | Pages: No page available

10.1161/jaha.121.025646 | PMID 35946474 Get It

Background The contribution of atrial cardiopathy to dementia risk is uncharacterized. We aimed to evaluate the association of atrial cardiopathy with incident dementia and potential mediation by atrial fibrillation (AF) and stroke. Methods and Results We conducted a prospective cohort analysis of participants in the ARIC (Atherosclerosis Risk in Communities) study attending visit 5 (2011–2013). We used Cox regression to determine the association between atrial cardiopathy and risk of dementia. Structural equation modeling methods were used to determine potential mediation by AF and/or stroke. Atrial cardiopathy was defined if ≥1 of the following at visit 5: P‐wave terminal force >5000 mV·ms in ECG lead V1, NT‐proBNP (N‐terminal pro–brain natriuretic peptide) >250 pg/mL or left atrial volume index ≥34 mL/m 2 by transthoracic echocardiography. We repeated our analysis necessitating ≥2 markers to define atrial cardiopathy. The prevalence of atrial cardiopathy was 34% in the 5078 participants (mean age 75 years, 59% female, 21% Black adults), with 763 participants developing dementia. Atrial cardiopathy was significantly associated with dementia (adjusted HR, 1.35 [95% CI, 1.16–1.58]), with strengthening of the effect estimate when necessitating ≥2 biomarkers (adjusted HR, 1.54 [95% CI, 1.25–1.89]). There was an increased risk of dementia among those with atrial cardiopathy when excluding those with AF (adjusted HR, 1.31 [95% CI, 1.12–1.55]) or stroke (adjusted HR, 1.28 [95% CI, 1.09–1.52]). The proportion of the effect mediated by AF was 4% ( P =0.005), and 9% was mediated by stroke ( P =0.048). Conclusions Atrial cardiopathy was significantly associated with an increased risk of dementia, with only a small percent mediation of the effect by AF or stroke.
Abstract 1507: Tumor only analysis of whole exome sequencing from a multi-institutional Nigerian prostate cancer cohort reveals DNA repair genes associated with African ancestry
Adeniji, Kayode , Jibrin, Paul, Obafunwa, John , Ogo, Chidiebere, Oluwole, Olabode P., Karanam, Balasubramanyam , Odedina, Folake T., Martin, Damali N. , Yates, Clayton , White, Jason , Kaninjing, Ernest , Faruk, Mohammed , Rotimi, Solomon O. , Popoola, Ademola , Fatiregun, Omolara , Tang, Wei , Ambs, Stefan

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 1507-1507

10.1158/1538-7445.am2022-1507 Get It

Abstract Men of African ancestry (MAA) have the highest global incidence and mortality of prostate cancer (PCa); however, the biology underlying this harsh disease presentation remains poorly understand, largely due to Africans and people within the African diaspora being under-represented in genomics research. MAA are younger at diagnosis, have higher tumor volume at diagnosis and have higher tumor aggression compared to European American men. Additionally, genomic profiling continues to show that PCa etiology and phenotype are influenced by higher amounts of African ancestry and that West African ancestry is associated with unique genomic alterations. Herein we utilize whole exome sequencing of a unique cohort of 45 advanced stage, treatment naïve Nigerian primary PCa tumors and 11 unmatched non-tumor tissue to compare genomic variants with African (AA) and European (EA) American TCGA PCa tumors. Nigerian samples were collected from 6 sites in central and southwest Nigeria. After whole exome sequencing, samples were processed using GATK best practices. Four genes [BRCA1 (100%), BARD1 (45%), BRCA2 (27%) and PMS2 (18%)] had germline variants in at least two Nigerian non-tumor samples. Across 111 germline variants, the AA cohort reflected a pattern [BRCA1 (68%), BARD1 (34%), BRCA2 (28%) and PMS2 (16%)] similar to Nigerian samples. Of the most frequently mutated genes, BRCA1 showed a statistically (p ≤ 0.05) higher mutation frequency in MAA. Disaggregating gene level mutation frequencies by variant revealed both ancestry linked and Nigerian specific germline variant patterns. Driven by rs799917, BRCA1 showed increasing mutation frequency as African admixture increased. BRCA2_rs11571831 was only present in MAA and BRCA2_rs766173 was increased in Nigerian men. 133 somatic variants were present in 26 PCa associated genes within the Nigerian tumor cohort. Nine genes [BRCA2 (27%), APC (20%), ATM (20%), BRCA1 (13%), DNAJC6 (13%), EGFR (13%), MAD1L1 (13%), MLH1 (11%) and PMS2 (11%)] showed mutation frequencies above 10%. Compared to TCGA cohorts, BRCA2, APC and BRCA1 showed statistically significant increases in Nigerian tumors. The Nigerian cohort variant pattern shared similarities (cosign similarities ≥ 0.734) with COSMIC signatures 5 and 6 and mutated genes showed significant (q < 0.001) GO and functional enrichment in mismatch repair and non-homologous repair deficiency (HRD) pathways. Here, we show that variants in DDR genes are increased in Nigerian PCa and that a portion of those variants correlate with increased African ancestry. Moreover, we identify variants of unknown significance that may contribute to population specific routes of tumorigenesis and treatment. These results present the most comprehensive characterization of the Nigerian PCa exome to date and further highlight the need to increase study population diversity. Citation Format: Jason A. White, Ernest Kaninjing, Kayode A. Adeniji, Paul Jibrin, John O. Obafunwa, Chidiebere N. Ogo, Mohammed Faruk, Solomon Rotimi, Ademola Popoola, Omolara A. Fatiregun, Olabode P. Oluwole, Balasubramanyam Karanam, Wei Tang, Stefan Ambs, Folake T. Odedina, Damali N. Martin, Clayton Yates. Tumor only analysis of whole exome sequencing from a multi-institutional Nigerian prostate cancer cohort reveals DNA repair genes associated with African ancestry [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1507.
Abstract 5891: The age-dependent association of risk factors with pancreatic cancer
Kim, Jihye , Wang, Qiao-Li , Babić, Ana , Li, Donghui , Petersen, Gloria M. , Perez, Kimberly , Ng, Kimmie , Giovannucci, Edward L. , Stampfer, Meir J., Wolpin, Brian M. , Yuan, Chen , Lee, Alice A. , Ámundadóttir, Laufey T. , Klein, Alison P. , McCullough, Marjorie L. , Risch, Harvey A. , Stolzenberg‐Solomon, Rachael Z. , Kraft, Peter

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 5891-5891

10.1158/1538-7445.am2022-5891 Get It

Abstract Importance: Pancreatic cancer presents as advanced disease in >80% of patients; yet, appropriate ages to consider prevention and early detection strategies are poorly defined. Objective: To investigate age-specific associations and attributable risks of pancreatic cancer for established modifiable and non-modifiable risk factors. Design, Setting, and Participants: We included 167,483 participants from 2 prospective U.S. cohort studies with 1190 incident cases of pancreatic cancer identified during >30 years of follow-up; 5107 pancreatic cancer cases and 8845 control participants of European ancestry from a completed multicenter genome-wide association study (GWAS); and 248,893 pancreatic cancer cases documented in the U.S. Surveillance, Epidemiology, and End Results (SEER) Program. Exposures: Across different age categories, we investigated cigarette smoking, obesity, diabetes, height, and non-O blood group in the prospective cohorts; weighted polygenic risk score of 22 previously identified single nucleotide polymorphisms in the GWAS; and male sex and Black race in the SEER program. Main outcomes and measures: Risk of developing pancreatic cancer by age evaluated by Cox, logistic, or Poisson regression, as determined by the study design. Results: In the prospective cohorts, all 5 risk factors were more strongly associated with pancreatic cancer risk among younger participants, with associations greatly attenuated among those over 70 years. The HRs comparing participants with 3-5 risk factors to those with no risk factors were 9.24 (95% CI, 4.11-20.77) among those aged ≤60 years, 3.00 (95% CI, 1.85-4.86) among those aged 61-70 years, and 1.46 (95% CI, 1.10-1.94) among those over 70 years (Pheterogeneity = 3×10-5). These factors together were related to 65.6%, 49.7%, and 17.2% of incident pancreatic cancers in these age groups, respectively. In the GWAS, the polygenic risk score was most strongly associated with pancreatic cancer risk among those aged ≤60 years, with lesser associations identified in older participants (Pheterogeneity = .01). In the SEER Program, male sex and Black race were also more strongly associated with pancreatic cancer risk among younger individuals (Pheterogeneity < 1×10-8). Conclusions and relevance: Inherited and lifestyle factors are more strongly associated with earlier-onset pancreatic cancer, emphasizing the importance of age at initiation for cancer prevention and control programs targeting this highly lethal malignancy. Citation Format: Chen Yuan, Jihye Kim, Qiao-Li Wang, Alice A. Lee, Ana Babic, PanScan/PanC4 I-III Consortium, Laufey T. Amundadottir, Alison P. Klein, Donghui Li, Marjorie L. McCullough, Gloria M. Petersen, Harvey A. Risch, Rachael Z. Stolzenberg-Solomon, Kimberly Perez, Kimmie Ng, Edward L. Giovannucci, Meir J. Stampfer, Peter Kraft, Brian M. Wolpin. The age-dependent association of risk factors with pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5891.
Insulin-Like Growth Factor (IGF)-1, IGF-Binding Protein-3, and Pancreatic Cancer in Male Smokers
Virtamo, Jarmo, Stolzenberg‐Solomon, Rachael Z. , Limburg, Paul J. , Pollak, Michaël , Taylor, Philip R. , Albanes, Demetrius

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 10, 2022 | Volume: 13 | Issue: 3 | Pages: 438-444

10.1158/1055-9965.438.13.3 Get It

Abstract To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50–69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95% CI 0.37–1.21, P trend = 0.17; OR = 0.70, 95% CI 0.38–1.27, P trend = 0.12; and OR = 0.85, 95% CI 0.50–1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions
Wirrell, Elaine , Nabbout, Rima , Scheffer, Ingrid E. , Alsaadi, Taoufik , Bogacz, Alicia, French, Jacqueline A. , Hirsch, Édouard , Jain, Satish, Kaneko, Sunao, Riney, Kate , Snead, O. Carter , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M. , Balestrini, Simona , Wiebe, Samuel , Cross, J. Helen , Perucca, Emilio , Wirrell, Elaine C , Samia, Pauline , Somerville, Ernest , Specchio, Nicola , Trinka, Eugen , Balestrini, Simona , Wiebe, Samuel , Cross, Helen J , Perucca, Emilio , Moshé, Solomon L , Hirsch, Edouard , French, Jacqueline , Scheffer, Ingrid E , Zuberi, Sameer M , Jain, Satish, Samia, Pauline , Trinka, Eugen , Moshé, Solomon L. , Tinuper, Paolo

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1333-1348

10.1111/epi.17237 | PMID 35503715 Get It

AbstractEpilepsy syndromes have been recognized for >50 years, as distinct electroclinical phenotypes with therapeutic and prognostic implications. Nonetheless, no formally accepted International League Against Epilepsy (ILAE) classification of epilepsy syndromes has existed. The ILAE Task Force on Nosology and Definitions was established to reach consensus regarding which entities fulfilled criteria for an epilepsy syndrome and to provide definitions for each syndrome. We defined an epilepsy syndrome as “a characteristic cluster of clinical and electroencephalographic features, often supported by specific etiological findings (structural, genetic, metabolic, immune, and infectious).” The diagnosis of a syndrome in an individual with epilepsy frequently carries prognostic and treatment implications. Syndromes often have age‐dependent presentations and a range of specific comorbidities. This paper describes the guiding principles and process for syndrome identification in both children and adults, and the template of clinical data included for each syndrome. We divided syndromes into typical age at onset, and further characterized them based on seizure and epilepsy types and association with developmental and/or epileptic encephalopathy or progressive neurological deterioration. Definitions for each specific syndrome are contained within the corresponding position papers.
Introduction to the epilepsy syndrome papers
Wirrell, Elaine , Perucca, Emilio , Perucca, Emilio , Moshé, Solomon L , Wirrell, Elaine C , Tinuper, Paolo , Moshé, Solomon L.

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1330-1332

10.1111/epi.17262 | PMID 35503711 Get It

International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions
Riney, Kate , Bogacz, Alicia, Somerville, Ernest , Hirsch, Édouard , Nabbout, Rima , Scheffer, Ingrid E. , Zuberi, Sameer M. , Alsaadi, Taoufik , Jain, Satish, French, Jacqueline A. , Specchio, Nicola , Wiebe, Samuel , Cabral‐Lim, Leonor , Naidoo, Ansuya , Perucca, Emilio , French, Jacqueline , Trinka, Eugen , Wiebe, Samuel , Auvin, Stéphane , Perucca, Emilio , Moshé, Solomon L , Wirrell, Elaine C , Hirsch, Edouard , Scheffer, Ingrid E , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M , Jain, Satish, Trinka, Eugen , Auvin, Stéphane , Moshé, Solomon L. , Wirrell, Elaine , Tinuper, Paolo

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1443-1474

10.1111/epi.17240 | PMID 35503725 Get It

AbstractThe goal of this paper is to provide updated diagnostic criteria for the epilepsy syndromes that have a variable age of onset, based on expert consensus of the International League Against Epilepsy Nosology and Definitions Taskforce (2017–2021). We use language consistent with current accepted epilepsy and seizure classifications and incorporate knowledge from advances in genetics, electroencephalography, and imaging. Our aim in delineating the epilepsy syndromes that present at a variable age is to aid diagnosis and to guide investigations for etiology and treatments for these patients.
ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions
Zuberi, Sameer M. , Wirrell, Elaine , Yozawitz, Elissa , Wilmshurst, Jo M. , Specchio, Nicola , Riney, Kate , Pressler, Ronit , Auvin, Stéphane , Samia, Pauline , Hirsch, Édouard , Galicchio, Santiago , Triki, Chahnez , Snead, O. Carter , Wiebe, Samuel , Cross, J. Helen , Scheffer, Ingrid E. , Perucca, Emilio , Nabbout, Rima , Scheffer, Ingrid E , Perucca, Emilio , Moshé, Solomon L , Nabbout, Rima , Wilmshurst, Jo M , Wirrell, Elaine C , Auvin, Stéphane , Yozawitz, Elissa G , Hirsch, Edouard , Cross, Helen J , Samia, Pauline , Specchio, Nicola , Zuberi, Sameer M , Triki, Chahnez , Wiebe, Samuel , Tinuper, Paolo , Moshé, Solomon L.

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1349-1397

10.1111/epi.17239 | PMID 35503712 Get It

Abstract The International League Against Epilepsy (ILAE) Task Force on Nosology and Definitions proposes a classification and definition of epilepsy syndromes in the neonate and infant with seizure onset up to 2 years of age. The incidence of epilepsy is high in this age group and epilepsy is frequently associated with significant comorbidities and mortality. The licensing of syndrome specific antiseizure medications following randomized controlled trials and the development of precision, gene‐related therapies are two of the drivers defining the electroclinical phenotypes of syndromes with onset in infancy. The principal aim of this proposal, consistent with the 2017 ILAE Classification of the Epilepsies, is to support epilepsy diagnosis and emphasize the importance of classifying epilepsy in an individual both by syndrome and etiology. For each syndrome, we report epidemiology, clinical course, seizure types, electroencephalography (EEG), neuroimaging, genetics, and differential diagnosis. Syndromes are separated into self‐limited syndromes, where there is likely to be spontaneous remission and developmental and epileptic encephalopathies , diseases where there is developmental impairment related to both the underlying etiology independent of epileptiform activity and the epileptic encephalopathy. The emerging class of etiology‐specific epilepsy syndromes, where there is a specific etiology for the epilepsy that is associated with a clearly defined, relatively uniform, and distinct clinical phenotype in most affected individuals as well as consistent EEG, neuroimaging, and/or genetic correlates, is presented. The number of etiology‐defined syndromes will continue to increase, and these newly described syndromes will in time be incorporated into this classification. The tables summarize mandatory features, cautionary alerts, and exclusionary features for the common syndromes. Guidance is given on the criteria for syndrome diagnosis in resource‐limited regions where laboratory confirmation, including EEG, MRI, and genetic testing, might not be available.
ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions
Hirsch, Édouard , French, Jacqueline A. , Scheffer, Ingrid E. , Bogacz, Alicia, Alsaadi, Taoufik , Sperling, Michael R. , Abdulla, Fatema , Zuberi, Sameer M. , Trinka, Eugen , Specchio, Nicola , Somerville, Ernest , Riney, Kate , Nabbout, Rima , Jain, Satish, Wilmshurst, Jo M. , Wiebe, Samuel , Perucca, Emilio , Connolly, Mary , Kochen, Silvia , French, Jacqueline , Samia, Pauline , Nabbout, Rima , Wilmshurst, Jo M , Auvin, Stéphane , Wiebe, Samuel , Perucca, Emilio , Moshé, Solomon L , Wirrell, Elaine C , Sperling, Michael R , Hirsch, Edouard , Scheffer, Ingrid E , Trinka, Eugen , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M , Samia, Pauline , Jain, Satish, Auvin, Stéphane , Moshé, Solomon L. , Tinuper, Paolo , Wirrell, Elaine

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1475-1499

10.1111/epi.17236 | PMID 35503716 Get It

Abstract In 2017, the International League Against Epilepsy (ILAE) Classification of Epilepsies described the “genetic generalized epilepsies” (GGEs), which contained the “idiopathic generalized epilepsies” (IGEs). The goal of this paper is to delineate the four syndromes comprising the IGEs, namely childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic–clonic seizures alone. We provide updated diagnostic criteria for these IGE syndromes determined by the expert consensus opinion of the ILAE’s Task Force on Nosology and Definitions (2017–2021) and international external experts outside our Task Force. We incorporate current knowledge from recent advances in genetic, imaging, and electroencephalographic studies, together with current terminology and classification of seizures and epilepsies. Patients that do not fulfill criteria for one of these syndromes, but that have one, or a combination, of the following generalized seizure types: absence, myoclonic, tonic‐clonic and myoclonic‐tonic‐clonic seizures, with 2.5–5.5 Hz generalized spike‐wave should be classified as having GGE. Recognizing these four IGE syndromes as a special grouping among the GGEs is helpful, as they carry prognostic and therapeutic implications.